Rheumatoid Arthritis PBMC Donors: Disease-State Portfolio and Clinical Annotation

Rheumatoid arthritis research depends on primary human immune cells that reflect the disease state. In vitro cell lines and murine models have fundamental limitations when the research question is about human synovial inflammation, joint-specific immune infiltration, or the response of patient-derived lymphocytes to candidate therapeutics. RA PBMC donors provide the primary human material that in vitro and translational RA programs require.

OrganaBio’s rheumatoid arthritis donor program provides annotated PBMC material from RA patients with documented disease activity, treatment history, and clinical metadata sufficient for translational immunology research. This page covers what’s in our RA donor portfolio, what clinical annotation we provide, which cell populations are available, and what to specify when selecting donors for your program.

Why Primary RA Donor Cells Matter for Research

RA is driven by synovial inflammation involving CD4+ T cells, B cells, macrophages, and fibroblast-like synoviocytes, but the peripheral blood immune compartment reflects disease activity in ways that make PBMCs informative for a range of research applications. Circulating CD4+ T helper subsets (Th1, Th17), regulatory T cells, B cell subsets (plasmablasts, memory B cells), and inflammatory monocytes all show altered frequency or activation state in active RA compared to healthy controls.

For programs developing RA therapeutics — disease-modifying antirheumatic drugs, JAK inhibitors, IL-6 pathway antagonists, anti-CD20 biologics, or novel targets — testing effects on primary RA donor cells provides a disease-relevant readout that healthy donor cells cannot replicate. The immune cell populations from an RA patient on active disease are phenotypically and functionally different from those of an age-matched healthy control, and those differences are the point of the model.

OrganaBio’s RA Donor Portfolio

RA donors in OrganaBio’s disease-state program are enrolled and characterized to meet the annotation requirements of translational immunology research. The minimum clinical data provided for each RA donation includes:

• Confirmed RA diagnosis per ACR/EULAR 2010 criteria. Donors are diagnosed based on joint involvement, serology (RF, anti-CCP), acute phase reactants, and symptom duration criteria.
• Disease Activity Score (DAS28). DAS28 using CRP or ESR is documented at or near time of collection, allowing researchers to stratify donors by remission (DAS28 below 2.6), low disease activity (2.6 to 3.2), moderate activity (3.2 to 5.1), or high activity (above 5.1).
• Seropositive vs. seronegative status. RF and anti-CCP antibody status is documented. Seropositive RA (RF+, anti-CCP+) and seronegative RA represent immunologically distinct disease subtypes with different immune profiles and treatment responses.
• Current medications and washout status. DMARDs (methotrexate, hydroxychloroquine, sulfasalazine), JAK inhibitors (tofacitinib, baricitinib, upadacitinib), and biologics (adalimumab, etanercept, abatacept, rituximab, tocilizumab) all affect peripheral blood immune cell populations and functional responses. Medication status is documented for all donors, with washout status specified where relevant.
• Disease duration from diagnosis.
• Joint involvement pattern. Number and type of affected joints documented where available.
• CRP and ESR at time of collection. Acute phase reactant levels provide additional disease activity context.
• HLA typing. HLA-DR4 (DRB1*04:01) and related shared epitope alleles are strongly associated with RA. HLA-typed donors allow researchers to stratify by RA genetic risk alleles.
• Donor age, sex, race/ethnicity, and disease duration.

Cell Populations Available From RA Donors

CD4+ T Helper Subsets

RA synovial tissue is enriched for Th1 and Th17 cells, and peripheral blood from active RA patients shows elevated Th17 frequencies compared to healthy controls. Th17 cells produce IL-17A, which drives synovial inflammation and osteoclastogenesis. For programs targeting Th17 differentiation or IL-17 pathway activity, RA donors provide higher baseline Th17 frequencies than healthy donors, making functional assays more sensitive at physiologically relevant cell frequencies.

Regulatory T Cells

Treg deficiency or dysfunction is documented in RA, with Tregs from RA patients showing reduced suppressive capacity relative to healthy donor Tregs. Programs studying Treg therapy or immune regulation in inflammatory arthritis benefit from RA donors specifically because the Treg functional deficit is part of the disease phenotype they are trying to model or correct.

B Cells and Plasma Cells

RA seropositive patients have activated autoreactive B cell populations producing RF and anti-CCP. Peripheral blood from active RA donors shows expanded plasmablast and plasma cell frequencies, particularly during disease flares. For programs targeting B cell activation, differentiation, or autoantibody production in RA, seropositive high-activity donors provide the most informative starting material.

Inflammatory Monocytes

RA is associated with expansion of the CD14+CD16+ intermediate and non-classical monocyte subsets compared to healthy controls. These populations are involved in TNF production and synovial macrophage recruitment. Programs studying monocyte activation, differentiation into synovial macrophages, or TNF pathway biology benefit from RA donor material with elevated CD16+ monocyte fractions.

Research Applications

• Drug candidate screening on primary RA donor cells: cytokine production assays, T cell activation, B cell differentiation, and signaling pathway inhibition studies
• Immune phenotyping comparison between active RA, remission, and healthy controls across T, B, NK, and monocyte compartments
• Mechanism of action studies for JAK inhibitors, anti-cytokine biologics, and novel targets using disease-state donor cells with relevant pathway activation
• Treg therapy research using RA donors with documented Treg deficiency as the target donor population
• Biomarker discovery across transcriptomic and proteomic platforms using annotated RA samples stratified by disease activity and serostatus
• Comparative studies using matched RA and healthy donor PBMCs from OrganaBio’s healthy donor pool, isolated under the same processing conditions for direct comparison

Selecting RA Donors for Your Research Program

Disease activity level. Specify whether your program needs active disease donors (DAS28 above 3.2), remission donors (DAS28 below 2.6), or both. Mechanistic studies typically need active disease; treatment response studies may need both.

Serostatus. Seropositive RA (RF+ and/or anti-CCP+) and seronegative RA have different immune profiles. Specify serostatus requirements upfront. Programs studying autoantibody-driven mechanisms specifically need seropositive donors. Programs studying RA pathogenesis more broadly may benefit from both serostatus populations.

Medication washout. For functional assays where JAK inhibitor or biologic treatment would confound the readout, specify medication-naive or washout-documented donors. Given that many RA patients are on chronic DMARDs, medication-naive RA donors are a smaller subset of the donor pool — discuss availability with OrganaBio’s donor management team before committing to a study design that requires medication-naive donors at scale.

HLA specification. For programs studying shared epitope alleles, MHC class II presentation in RA, or T cell receptor repertoire studies, specify HLA-DR4 (DRB1*04:01) donors or other specific allele requirements. OrganaBio’s HLA-typed donor pool enables this selection.

Post-Thaw Specifications

OrganaBio’s quality standard for released disease-state cryopreserved PBMCs, including RA donors, is greater than 80% post-thaw viability. RA donor material is processed under the same receipt-to-processing standards as other disease-state collections, with the same attention to handling time and processing quality that applies across OrganaBio’s donor program.

Frequently Asked Questions

Are RA donors available in active disease or only remission?

Both. OrganaBio’s RA donor pool includes donors across the disease activity spectrum, from remission to high disease activity. DAS28 scores are documented at or near time of collection. Specify your disease activity requirements when requesting donors, and OrganaBio’s team will identify available donors that match.

Can I request RA donors not taking biologics or JAK inhibitors?

Yes, but availability is more limited since most RA patients with active disease are on some form of DMARD therapy. Discuss your medication requirements with OrganaBio’s team upfront, including whether DMARD-only donors are acceptable or whether you specifically need biologic- and JAK inhibitor-naive material.

Is RA PBMC material available for GMP manufacturing?

No. OrganaBio’s disease-state donor materials are for research use only (RUO). For programs developing autologous cell therapies for RA patients, contact OrganaBio’s clinical team to discuss program-specific starting material requirements under the appropriate regulatory framework.

Requesting RA Donor Material

To discuss RA donor availability, clinical annotation options, and delivery timelines, contact OrganaBio’s team. Provide your disease activity requirements, serostatus specifications, medication history requirements, and the cell populations most relevant to your research application.